Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BMS-986465
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BMS-986465 is an oral, central nervous system (CNS)-penetrant small molecule inhibitor of tyrosine-protein kinase 2 (TYK2), developed by Bristol Myers Squibb for the treatment of neuroinflammatory diseases. Its mechanism of action involves selective inhibition of TYK2, a non-receptor tyrosine kinase implicated in cytokine signaling pathways relevant to neuroinflammation. The drug is currently in Phase 1 clinical trials for neuroinflammation and multiple sclerosis[1][4][7].
- Other names
- TYK2i-CNSTYK-2i-CNSTYK 2i-CNS
02
Targets
TYK2 JH2 (Tyrosine kinase 2 Janus homology 2 pseudokinase domain)
Beyond the preview
Go deeper on BMS-986465.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BMS-986465.